Cargando…
Structural basis for ineffective T-cell responses to MHC anchor residue-improved “heteroclitic” peptides
MHC anchor residue-modified “heteroclitic” peptides have been used in many cancer vaccine trials and often induce greater immune responses than the wild-type peptide. The best-studied system to date is the decamer MART-1/Melan-A(26–35) peptide, EAAGIGILTV, where the natural alanine at position 2 has...
Autores principales: | Madura, Florian, Rizkallah, Pierre J, Holland, Christopher J, Fuller, Anna, Bulek, Anna, Godkin, Andrew J, Schauenburg, Andrea J, Cole, David K, Sewell, Andrew K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357396/ https://www.ncbi.nlm.nih.gov/pubmed/25471691 http://dx.doi.org/10.1002/eji.201445114 |
Ejemplares similares
-
TCR‐induced alteration of primary MHC peptide anchor residue
por: Madura, Florian, et al.
Publicado: (2019) -
TCR/pMHC Optimized Protein crystallization Screen
por: Bulek, Anna M., et al.
Publicado: (2012) -
Minimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimers
por: Holland, Christopher J., et al.
Publicado: (2012) -
Enhanced Detection of Antigen-Specific CD4(+) T Cells Using Altered Peptide Flanking Residue Peptide–MHC Class II Multimers
por: Holland, Christopher J., et al.
Publicado: (2015) -
T-cell Receptor (TCR)-Peptide Specificity Overrides Affinity-enhancing TCR-Major Histocompatibility Complex Interactions
por: Cole, David K., et al.
Publicado: (2014)